Our mission is to accelerate the timelines of pre-clinical and translational research of drug candidates into clinical trials for patients in need of novel therapies.
- De-risk investment decisions through reproducibility
- Source and apply innovative platforms and techniques
- Help our partners broaden the therapeutic applications of their results
- Repurpose drug candidates that have potential in diseases of unmet need
We design assays for partners based on understanding the immune cells involved in disease pathogenesis. Our team continuously monitors the recent developments and clinical trials to incorporate these findings into pre-clinical research.
Immunaccel operates in a capital efficient manner and in turn provides cost-effective development of assays for our partners. We have assembled a team of scientists, clinicians , technologists and business minds to successfully develop and deliver assays to our partners.
- Founder of Immunaccel and Head of Immune 3D
- Managing Partner, Equidis Ventures and Envisage Life Sciences Partners
- Former Director of Business Development, Amplimmune (acquired by Astrazeneca/MedImmune 2013)
- B.S. Molecular Genetics, The Ohio State University and MS/MBA Carey School of Business (JHU)
- Enjoys business development, strategy, science and building young companies from scratch
- Associate Professor, Microbiology and Immunology
- Founder and CEO, Webbcures LLC
- Leading immunologist and research scientist who is recognized for her studies focused on the modulation of CD1d-mediated NKT cell activation for cancer immunotherapy using natural and artificial platforms
- PhD, Microbiology and Immunology (Indiana University) and Post-doctoral fellow, Immunology (Johns Hopkins)
- Enjoys mentoring the next generation of scientists
- Head of Healthcare and Life Sciences Strategy at Hewlett Packard
- Managing Partner, Equidis Ventures
- Former Head of Business Development at Sony DADC (part of Sony Corporation)
- PhD in Biochemistry from J.W. Goethe University (Germany) and Business at U.C. Berkley Haas School and MIT Sloan School of Management
- Ali enjoys entrepreneurship and advising start-ups
- Head of Operations at GRAIL
- Former, Head of Operations at Verily
- Co-founder of Rooster Bio – an innovative stem cell company (Maryland)
- PhD in Biochemistry and MBA, Wharton School of Business
- Entrepreneurial, experienced operations executive and enjoys building start-ups
How can I receive your Schedule of Assays?
Please sign up onto our mailing list via our website and you will receive our upcoming schedule.
What do I need to have in place before working with Immunaccel?
A Master Services Agreement (MSA), a Purchase Order (PO) number and signed Statement of Work (SOW) are required to initiate a study. We can work with your MSA template or can provide ours.
How can I Build-a-System?
Once you select a cell platform, you can send us a draft protocol or design concept. Our team will review and provide an estimate?
How can I reserve a position in your Schedule Assay run?
Our Schedule Assays are on a first-come, first-serve basis. If we have an MSA in place – it’s easy. Simply send our team an e-mail and we will get back to you on the availability.
When can I expect my results?
For our Scheduled Assay runs we expect a 2-3 week turnaround. More complex projects are handled on a case-by-case basis.
Can you procure patient samples in other cancer types?
Yes – please contact us to discuss your interests in the context of our assay platforms.
Can I license your cell platforms?
Depending on the scope of projects – we can consider licensing our cell platforms under a partnership.
Do you sell patient samples for research use?
No – Immunaccel is not in the business of selling patient derived samples.